The Latest Analyst Ratings for RAPT Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, RAPT Therapeutics (NASDAQ:RAPT) received 3 bullish and 1 somewhat bullish ratings from analysts. The average 12-month price target for the company is $39.25, representing an 8.72% decrease from the previous average price target of $43.00.
August 09, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RAPT Therapeutics received positive ratings from analysts, but the average 12-month price target decreased.
The positive ratings from analysts indicate a positive outlook for RAPT Therapeutics. However, the decrease in the average 12-month price target suggests that analysts expect the stock price to decrease in the future.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100